J.P. Morgan Notebook Day 3: Regeneron, AstraZeneca CRISPR And Juno
This article was originally published in Scrip
You may also be interested in...
Three CRISPR/Cas9 patent owners and four companies that license the intellectual property – CRISPR, Intellia, Caribou and ERS – signed a formal agreement to protect their patent rights and cross-license necessary IP while a patent interference proceeding is ongoing.
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.